WO2020090974A1 - Biocapteur - Google Patents

Biocapteur Download PDF

Info

Publication number
WO2020090974A1
WO2020090974A1 PCT/JP2019/042761 JP2019042761W WO2020090974A1 WO 2020090974 A1 WO2020090974 A1 WO 2020090974A1 JP 2019042761 W JP2019042761 W JP 2019042761W WO 2020090974 A1 WO2020090974 A1 WO 2020090974A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
biosensor
enzyme
mutant
vesicle
Prior art date
Application number
PCT/JP2019/042761
Other languages
English (en)
Japanese (ja)
Inventor
上田　宏
九龍 蘇
哲也 北口
有紀 大室
フーン ショーン
ベー サイラス
Original Assignee
国立大学法人東京工業大学
エージェンシー フォー サイエンス、テクノロジー アンド リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人東京工業大学, エージェンシー フォー サイエンス、テクノロジー アンド リサーチ filed Critical 国立大学法人東京工業大学
Publication of WO2020090974A1 publication Critical patent/WO2020090974A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/40—Apparatus specially designed for the use of free, immobilised, or carrier-bound enzymes, e.g. apparatus containing a fluidised bed of immobilised enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Definitions

  • the present invention relates to an antibody detection biosensor, a method for manufacturing the biosensor, and a method for detecting an antibody using the biosensor.
  • the present invention also relates to an antigen detection biosensor and a method for detecting an antigen using the biosensor.
  • GUS ⁇ -glucuronidase
  • the above-mentioned measurement method utilizes such a property of GUS, and there are two types of fusion proteins, that is, a fusion protein containing an antibody V H region and a GUS variant and a fusion protein containing an antibody V L region and a GUS variant.
  • a fusion protein containing an antibody V H region and a GUS variant
  • a fusion protein containing an antibody V L region and a GUS variant Use a fusion protein.
  • the principle of this measuring method is as follows. If the sample does not exist antigen, since remains weak interaction V H and V L domains, the most tetramer dimer in intact variant of GUS connecting the V H region and the V L region Don't
  • the antigen is present in the sample, the interaction between the V H and V L regions is strengthened, and this interaction also binds the dimer of the GUS mutant linked to the V H and V L regions. Then, it forms a tetramer and becomes active. Therefore, the amount of antigen in the sample can
  • Patent Document 1 is a method capable of detecting an antigen with high sensitivity, but in the use in the medical field such as clinical diagnosis, a detection method with higher sensitivity is required.
  • the present invention has been made under such a background, and an object thereof is to provide a highly sensitive homogeneous immunoassay means.
  • the present inventor is a biosensor comprising a fusion protein containing a GUS variant into which a mutation that inhibits tetramer formation is introduced and a His tag, and a vesicle composed of a lipid membrane.
  • a biosensor in which the His tag is located outside the vesicle and the GUS mutant is located inside the vesicle, which penetrates the lipid membrane of the vesicle, and this biosensor is highly sensitive to the antibody that binds to the His tag. It was found that can be detected by.
  • the antigen that binds to the antibody variable region can be detected with high sensitivity. Also found.
  • the present invention has been completed based on the above findings. That is, the present invention provides the following [1] to [16].
  • a biosensor for detecting an antibody that binds to a peptide comprising: 1) a fusion protein containing a variant of an enzyme activated by formation of a multimer, a transmembrane domain, and the peptide, and 2) A) a vesicle composed of a lipid membrane, wherein A) the mutant of the enzyme is a mutant into which a mutation that reduces the binding affinity between monomers is introduced, and B) the transmembrane domain has the small size.
  • Penetrate the lipid membrane of the vesicle C) a variant of the enzyme that is activated by the formation of the multimer is exposed inside the vesicle, and D) the peptide is exposed outside the vesicle.
  • [3] A mutant of ⁇ -glucuronidase, wherein 51st phenylalanine in the amino acid sequence of Escherichia coli ⁇ -glucuronidase is replaced with tyrosine, 64th alanine is replaced with valine, 185th aspartic acid is replaced with asparagine, and 516th position Methionine is replaced with lysine, 525th tyrosine is replaced with phenylalanine, 559th glycine is replaced with serine, 567th lysine is replaced with arginine, 585th glutamine is replaced with histidine, and 601st position.
  • the method for producing a biosensor comprises the following steps (1) to (5): (1) Includes a vector expressing a fusion protein containing a mutant of an enzyme activated by the formation of a multimer, a transmembrane domain and a peptide, a reagent required for cell-free transcription, and a reagent required for cell-free translation Preparing an aqueous solution, (2) A step of dispersing the aqueous solution prepared in step (1) in an oil phase containing phospholipids and cholesterol to produce a W / O emulsion, (3) A step of forming a liposome containing the vector and the reagent inside in an aqueous solution by overlaying the W / O emulsion generated in step (2) on the aqueous solution and sedimenting by centrifugation. (4) a step of collecting the liposome formed in the step (3), (5) A step of advancing transcription and translation reactions in the liposome recovered in step (4).
  • a method for detecting an antibody in a sample comprising the step of contacting the sample with the biosensor according to any one of [1] to [6], and detecting the formation of a multimer by a change in enzyme activity.
  • a method for detecting an antibody which comprises a step.
  • a biosensor for detecting an antigen that binds to an antibody variable region comprising: 1) a first fusion protein containing a variant of an enzyme that is activated by the formation of a multimer, a transmembrane domain, and a peptide. 2) a second fusion protein containing the antibody variable region and a protein having an affinity for the peptide, and 3) a vesicle composed of a lipid membrane, A mutant into which a mutation that reduces binding affinity between the bodies is introduced, B) the transmembrane domain penetrates the lipid membrane of the vesicle, and C) an enzyme that is activated by the formation of the multimer.
  • the ⁇ -glucuronidase mutant has a configuration in which the 51st phenylalanine in the amino acid sequence of Escherichia coli ⁇ -glucuronidase is replaced by tyrosine, the 64th alanine is replaced by valine, the 185th aspartic acid is replaced by asparagine, and the 516th position.
  • Methionine is replaced with lysine
  • 525th tyrosine is replaced with phenylalanine
  • 559th glycine is replaced with serine
  • 567th lysine is replaced with arginine
  • 585th glutamine is replaced with histidine, and 601st position.
  • the biosensor according to [10] wherein the glycine is a mutant in which aspartic acid is substituted.
  • a method for detecting an antigen in a sample which comprises contacting the sample with the biosensor according to any of [9] to [15], and detecting the formation of a multimer by a change in enzyme activity.
  • a method for detecting an antigen which comprises a step.
  • the present invention provides a novel biosensor. Since this biosensor can detect a substance easily and with high sensitivity, it is expected to be used in the medical field such as clinical diagnosis.
  • the upper left is an image when expressing His 6 -GUS_IV5_KY and His 6 -TM-GUS_IV5_KY vector, and an anti-His antibody is added
  • the lower left is expressing His 6 -GUS_IV5_KY and His 6 -TM-GUS_IV5_KY vector, and anti-His
  • the image when no antibody was added the upper right is an image when only the His 6 -GUS_IV5_KY vector was expressed, and the image when an anti-His antibody was added, the lower right is only the His 6 -GUS_IV5_KY vector was expressed, and the anti-His It is an image when an antibody is not added.
  • the antibody-detecting biosensor of the present invention is a biosensor for detecting an antibody that binds to a peptide, and is 1) a mutant of an enzyme and a transmembrane domain that are activated by the formation of a multimer. And a peptide containing the above-mentioned peptide, and 2) a vesicle composed of a lipid membrane, and A) a mutant of the enzyme, wherein the mutant has a mutation that reduces binding affinity between monomers.
  • the transmembrane domain penetrates the lipid membrane of the vesicle
  • a biosensor wherein the peptide is exposed to the outside of the vesicle.
  • This biosensor contains a fusion protein and a vesicle.
  • the fusion protein penetrates the lipid membrane of the vesicles, the peptide portion that binds the antibody is exposed outside the vesicle, and the enzyme portion is exposed inside the vesicle.
  • the enzyme does not form a multimer and is not activated because a mutation that reduces the binding affinity between the monomers is introduced. Therefore, even if an enzyme substrate is present, reaction products such as fluorescent substances are scarcely produced.
  • the two peptides exposed on the outside of the vesicle are attracted to the antibody, whereby the enzyme moiety linked to the peptide binds, forms a multimer, and is activated.
  • a reaction product is generated in the vesicle by the activated enzyme, but since this reaction product is concentrated in the vesicle, even a trace amount can be easily detected.
  • enzyme activation occurs for each vesicle, vesicles that produce a reaction product and vesicles that do not produce a reaction product occur unless the amount of antibody is very large. Since the number of vesicles that produce a reaction product increases depending on the amount of antibody, the amount of antibody can be grasped as the “number” of vesicles.
  • the enzyme that is activated by the formation of a multimer means an enzyme that exhibits activity or improves activity only when several monomers are bound.
  • the number of monomers constituting the multimer is not particularly limited, and an enzyme that activates any of a dimer, a trimer, a tetramer, a pentamer, a hexamer and the like may be used.
  • the enzyme activated by the formation of the multimer is preferably an enzyme whose activity can be easily detected or measured. For example, an enzyme that can detect or measure a product or a substrate based on the absorbance, fluorescence intensity, and emission intensity.
  • enzymes that are activated by the formation of multimers include those commonly used as reporter enzymes, for example, ⁇ -glucuronidase (activated by tetramer), ⁇ -galactosidase (activated by tetramer). , Alkaline phosphatase (activated by dimer), malate dehydrogenase (activated by dimer) and the like.
  • the mutations that reduce the binding affinity between the monomers include the mutations introduced at the binding sites between the monomers. For many enzymes that are activated by the formation of multimers, the amino acid sequence and the binding site between the monomers have been clarified. Understand how affinity can be reduced. The degree of decrease in affinity may be such that the formation of multimers becomes difficult due to the decrease in binding affinity between the monomers, and thus the difference in activity from the wild-type enzyme can be recognized. Mutants in which mutations that reduce the binding affinity between monomers are introduced include those with reduced affinity for all bonds between monomers, as well as the affinity for some bonds between monomers. It also includes the ones that have decreased only.
  • a mutant that forms a dimer but does not easily form a tetramer such as a ⁇ -glucuronidase mutant described below, is also introduced with a mutation that reduces the binding affinity between the monomers. Included in the mutant.
  • mutant in which the binding affinity between the monomers is reduced a mutant in which the 516th methionine and / or the 517th tyrosine in the amino acid sequence of Escherichia coli ⁇ -glucuronidase is substituted with another amino acid is given.
  • other amino acid substituted with the 516th methionine include lysine
  • examples of the other amino acid substituted with the 517th tyrosine include glutamic acid.
  • a mutation may be introduced into the ⁇ -glucuronidase mutant in addition to the above-mentioned mutation that decreases the binding affinity between the monomers.
  • An example of such a mutation is a mutation that improves thermostability.
  • a large number of references for example, Flores H. et al., J Mol Biol. 2002 Jan 18; 315 (3): 325-37 describe what mutations should be introduced to improve the thermostability of ⁇ -glucuronidase. As described, the person skilled in the art can identify the mutations according to those documents.
  • mutations that improve the thermostability of ⁇ -glucuronidase include a mutation in which the 27th asparagine in the amino acid sequence of Escherichia coli ⁇ -glucuronidase is replaced with tyrosine, a mutation in which the 51st phenylalanine is replaced with tyrosine, and a 64th mutation.
  • Alanine is replaced with valine, 185th aspartic acid is replaced with asparagine, 349th isoleucine is replaced with phenylalanine, 369th asparagine is replaced with serine, 525th tyrosine Is a mutation in which is substituted with phenylalanine, a mutation in which glycine at position 559 is replaced with serine, a mutation in which lysine at position 567 is replaced with arginine, a mutation in which phenylalanine at position 582 is replaced with tyrosine, and a glutamine at position 585 are histidine Placed in Mutation, substitution of 601st glycine with aspartic acid (these mutations are Flores H.
  • the position of the above-mentioned amino acid mutation indicates the position in the amino acid sequence of ⁇ -glucuronidase derived from Escherichia coli, so in the amino acid sequences of ⁇ -glucuronidase derived from other organisms, the amino acid corresponding to the above-mentioned position may not exist. .. In such a case, the amino acid sequence is aligned with the amino acid sequence of ⁇ -glucuronidase derived from Escherichia coli on the basis of the amino acid sequence identity, thereby identifying the position of the amino acid mutation.
  • the amino acid sequence of wild-type ⁇ -glucuronidase derived from Escherichia coli is shown in SEQ ID NO: 1.
  • suitable ⁇ -glucuronidase mutants include a mutant in which the 516th methionine in the amino acid sequence of Escherichia coli ⁇ -glucuronidase is replaced with lysine, and the 517th tyrosine is replaced with glutamic acid (see International Publication No. 2017/130610. 51) phenylalanine in the amino acid sequence of Escherichia coli ⁇ -glucuronidase is replaced with tyrosine, 64th alanine is replaced with valine, 185th aspartic acid is replaced with asparagine, and 516th methionine.
  • the transmembrane domain in the present invention may be any as long as it allows the fusion protein to penetrate the lipid membrane of vesicles.
  • the transmembrane domain in the present invention the whole or a part of the transmembrane domain of a natural membrane protein can be used as it is, but those into which a mutation is introduced may be used.
  • Suitable transmembrane domains can include the transmembrane domain of human epidermal growth factor receptor (EGFR).
  • the peptide in the present invention is not limited to a particular peptide, but a short peptide is preferable because it is difficult to expose it to the outside of the vesicle when the number of amino acid residues is large.
  • the number of amino acid residues in the peptide is preferably 3 to 25, more preferably 5 to 20.
  • Peptides are also protein tags such as His tag, Spy tag 002 (Keeble AH et al., Angew Chem Int Ed Engl. 2017 Dec 22; 56 (52): 16521-16525), Snoop tag (Vegginiani F et al). ., Proc. Natl. Acad. Sci. USA113 (5): 1202-1207, 2016), HA tags, myc tags, and FLAG tags are preferable.
  • the variant of the enzyme activated by the formation of the multimer, the transmembrane domain, and the peptide are arranged in this order, but the variant of the enzyme activated by the formation of the multimer is N-terminal and the variant of the enzyme is also C-terminal.
  • the variant of the enzyme that is activated by the formation of multimers may be C-terminal and the peptide N-terminal.
  • the fusion protein may consist of only the mutant enzyme, transmembrane domain, and peptide that are activated by the formation of multimers, but may also contain other peptides or proteins.
  • the fusion protein may also contain a linker between the variant of the enzyme that is activated by the formation of multimers and the transmembrane domain and / or between the transmembrane domain and the peptide.
  • the linker may be any one as long as it can normally function the mutant of the enzyme which is activated by the formation of the multimer, the transmembrane domain, and the peptide.
  • the length of the linker varies depending on the type of enzyme, transmembrane domain, and peptide used, but is usually 10 to 60 ⁇ , preferably 30 to 40 ⁇ .
  • the number of amino acids in the linker may be any number so long as it has the above-mentioned length, but is usually 5 to 50, preferably 15 to 20.
  • the amino acid sequence of the linker may be the same as the amino acid sequence of a general linker used when producing a fusion protein. Specifically, Gly-Gly-Gly-Gly-Ser (G 4 S) repeat sequence (repetition number is usually 2 to 5), Glu-Ala-Ala-Ala-Lys (EAAAK) repeat sequence, Asp- Asp-Ala-Lys-Lys (DDAKK) repeat sequence and the like can be mentioned.
  • One mutant of the enzyme that is activated by the formation of the multimer may be contained in the fusion protein, but two or more mutants may be contained in the fusion protein.
  • two variants of the enzyme are included, they are arranged adjacent to each other via a linker.
  • the linker used at this time may be the same as the above-mentioned linker.
  • Vesicles composed of lipid membranes may be similar to liposomes used for artificial cells.
  • the component of the lipid membrane may be the same as the component of a general liposome membrane, and examples thereof include phospholipid and cholesterol.
  • Phospholipids include 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-palmitoyl-2-oleoyl- Mention may be made of sn-glycero-3-phosphocholine (POPC), of which POPC is preferably used.
  • POPC sn-glycero-3-phosphocholine
  • the size of the vesicles may be about the same as that of liposomes used for artificial cells and the like. Vesicles can be prepared in the same manner as general liposomes.
  • the biosensor of the present invention contains a fusion protein and vesicles, but may contain other substances.
  • the enzyme activated by the formation of multimers is ⁇ -glucuronidase
  • the biosensor of the present invention has the following advantages. 1) Homogeneous measurement is possible, and the antibody can be measured simply and quickly. 2) Since the enzymatic reaction is carried out in a narrow space within the vesicle, the reaction product is not diluted and the antibody can be measured with high sensitivity. 3) The vesicles to which the antibody is bound emit a signal such as fluorescence, and the vesicles to which the antibody is not bound do not emit a signal, so that the signal can be binarized and the influence of measurement error can be reduced.
  • the method for producing a biosensor of the present invention is a method for producing the above-mentioned antibody detection biosensor, which is characterized by including the following steps (1) to (5). ..
  • An aqueous solution containing reagents is prepared.
  • a commercially available expression vector into which a gene encoding the fusion protein is inserted can be used.
  • a reagent necessary for cell-free transcription a reagent used in a general cell-free transcription reaction can be used, and examples thereof include ribonucleotide, RNA polymerase, transcription cofactor and the like.
  • a reagent required for cell-free translation a reagent used in a general cell-free translation reaction can be used, and examples thereof include amino acids, ribosomes, and translation cofactors. Since reagents necessary for cell-free transcription and reagents necessary for cell-free translation are commercially available, commercially available products may be used.
  • the concentrations of the vector and the reagent in the aqueous solution are not particularly limited, and may be the same as those in general cell-free transcription reaction and cell-free translation reaction.
  • step (2) the aqueous solution prepared in step (1) is dispersed in an oil phase containing phospholipids and cholesterol to form a W / O emulsion.
  • the amount of the aqueous solution dispersed in the oil phase is not particularly limited as long as it is an amount capable of forming a W / O emulsion.
  • the concentrations of phospholipid and cholesterol in the oil phase are not particularly limited, and may be the same as those in a general method for producing a W / O emulsion.
  • the W / O emulsion generated in the step (2) is overlaid on the aqueous solution, and then centrifuged to precipitate the liposome, which contains the vector and the reagent therein, in the aqueous solution. ..
  • the aqueous solution may be any as long as it can form an aqueous phase for the W / O emulsion (oil phase).
  • the conditions of centrifugation are not particularly limited, and may be the same as the conditions in a general method for forming liposomes.
  • step (4) the liposomes formed in step (3) are collected.
  • the method for collecting the liposomes is not particularly limited, and for example, when an oil phase is formed in the upper part of the tube and an aqueous phase is formed in the lower part, and centrifugation is performed, the bottom part of the tube may be perforated to collect the liposomes. it can.
  • step (5) transcription and translation reactions proceed in the liposomes collected in step (4).
  • the method for detecting an antibody of the present invention is a method for detecting an antibody in a sample, which comprises contacting the sample with the antibody detection biosensor described above, It is characterized by having a step of detecting by a change.
  • the sample may be any sample as long as it may contain the antibody to be detected.
  • the contact method between the sample and the biosensor is not particularly limited, but usually it is carried out by allowing the sample and the biosensor to coexist in a solution.
  • Conditions such as temperature, time, pH of the solution, and amount of the biosensor used in this contacting step may be those generally used for the enzyme contained in the biosensor.
  • the temperature in this contacting step is preferably about 20 to 37 ° C.
  • the contacting time is preferably about 10 to 60 minutes
  • the pH of the solution is 6.8 to 7
  • the concentration of the biosensor in the solution is preferably about 10 to 100 nM.
  • the formation of multimers can be detected by the change (increase or expression) in the activity of the enzyme mutant contained in the biosensor.
  • the activity of the enzyme variant contained in the biosensor can be measured by an activity measuring method generally used for the enzyme.
  • the activity can be measured by adding a chromogenic substrate or a fluorescent substrate and quantifying a substance produced from the substrate.
  • chromogenic substrates for ⁇ -glucuronidase include X-Gluc, 4-nitrophenyl ⁇ -glucopyranoside, 4-nitrophenyl ⁇ -D-glucuronide, and the like
  • fluorescent substrates include 4-methylumbelliferyl- ⁇ -D- Examples thereof include glucuronide, fluorescein di- ⁇ -D-glucuronide, fluorescein di- ⁇ -D-glucuronide and dimethyl ester.
  • the substances produced from these substrates can be quantified by measuring the absorbance at a specific wavelength, the fluorescence intensity and the like.
  • the product can be quantified by measuring the absorbance around 405 nm, and if the substrate is 4-methylumbelliferyl- ⁇ -D-glucuronide, the product can be 340 The product can be quantified by exciting with fluorescence of nm and measuring the fluorescence intensity around 480 nm.
  • the substrate is membrane-permeable like fluorescein di- ⁇ -D-glucuronide and dimethyl ester, and the fluorescent substance of the product is water-soluble like fluorescein, the substrate is added from the outside of the liposome and reacted, It is preferable because the fluorescence of the product in each liposome can be individually detected.
  • the antigen detection biosensor of the present invention comprises an antibody variable region and a protein having an affinity for the peptide in the peptide portion exposed to the outside of the vesicle in the antibody detection biosensor of the present invention.
  • a biosensor for detecting an antigen that binds to an antibody variable region and more specifically, 1) a mutation of an enzyme that is activated by the formation of a multimer.
  • A) the mutant of the enzyme is a mutant into which a mutation that reduces the binding affinity between monomers has been introduced, and B) the transmembrane domain.
  • B) the transmembrane domain In penetrates the lipid membrane of the vesicle, C) a variant of the enzyme that is activated by the formation of the multimer is exposed inside the vesicle, and D) the peptide is outside the vesicle.
  • the biosensor which is exposed and which has the affinity with the peptide E), binds to the peptide exposed to the outside of the vesicle.
  • the biosensor includes a first fusion protein, a second fusion protein, and vesicles.
  • the first fusion protein penetrates the lipid membrane of the vesicle, exposing the peptide portion outside the vesicle and the enzyme portion inside the vesicle.
  • the protein portion showing affinity for the peptide in the second fusion protein binds to the peptide portion in the first fusion protein, so that the vesicle exposes the antibody variable region to the outside.
  • the enzyme does not form a multimer and is not activated because the mutation that reduces the binding affinity between the monomers is introduced.
  • reaction products such as fluorescent substances are scarcely produced.
  • the two antibody variable regions exposed outside the vesicle are attracted to the antigen. Since the antibody variable region is indirectly linked to the enzyme part inside the vesicle, the two antibody variable regions are attracted to the antigen, and the enzyme part inside the vesicle binds to form a multimer, Activate. A reaction product is generated in the vesicle by the activated enzyme, but since this reaction product is concentrated in the vesicle, even a trace amount can be easily detected.
  • vesicles that produce reaction products and vesicles that do not produce reaction products occur unless the amount of antigen is very large. Since the number of vesicles that produce a reaction product increases depending on the amount of antigen, it is possible to grasp the amount of antigen as the “number” of vesicles.
  • the same biosensors as those of the antibody detection biosensor of the present invention can be used.
  • the protein having an affinity for the peptide is not particularly limited, and can be appropriately selected according to the type of peptide.
  • An example of a combination of a peptide and a protein having an affinity for the peptide is Spy tag and Spy catcher. When Spy tag and Spy catcher are mixed, they form an isopeptide bond (Keeble AH et al., Angew Chem Int Ed Engl. 2017 Dec 22; 56 (52): 16521-16525).
  • a derivative of Spy tag capable of binding to the Spy catcher can be used, and in place of the Spy catcher, a derivative of Spy catcher capable of binding to the Spy tag can be used.
  • Snoop tag and Snoop catcher that has orthogonality with this (Vegginiani F et al., Proc. Natl. Acad. Sci. USA 113 (5): 1202-1207, 2016) is used for Alternatively or simultaneously, they can be used.
  • Snoop tags and Snoop catchers as with Spy tags and Spy catchers, these derivatives can be used instead of Snoop tags and Snoop catchers.
  • a V H region or V L region of an ordinary antibody (IgG), a single chain antibody scFv or Fab region can be used, but a VHH (camel that forms a dimer by antigen binding) Derived H chain antibody) (Chang HJ et al., ACS Synth Biol. 2018 Jan 19; 7 (1): 166-175, Sonneson GJ et al., Biochemistry. 2009 Jul 28; 48 (29): 6693-5. ) Is preferably used.
  • the antibody variable region can select the variable region of any antibody according to the antigen to be detected, and is not limited to the variable region of a specific antibody. Specifically, the variable region of an antibody that specifically binds to an antigen to be detected, which will be described later, can be used.
  • the second fusion protein may consist of only the antibody variable region and the protein showing affinity for the peptide, but may also contain other peptides or proteins.
  • the second fusion protein may include a linker between the antibody variable region and the protein membrane showing affinity for the peptide.
  • the linker may be the same as the linker contained in the fusion protein in the antibody detection biosensor described above.
  • the antigen detection method of the present invention is a method for detecting an antigen in a sample, which comprises the step of contacting the sample with the above biosensor, and the formation of a multimer by changing the enzymatic activity. It is characterized by having a step of detecting.
  • the antigen to be detected is not particularly limited, and a low molecular weight compound (for example, a compound having a molecular weight of 1000 or less) may be a detection target, and a high molecular compound such as a protein may be a detection target.
  • the detection of high molecular weight proteins can be performed using two single chain antibodies or Fab fragments. Further, since the method of the present invention can be used for diagnosis of diseases, food toxicity test, environmental analysis, etc., it is preferable to target substances related to these.
  • neonicotinoid pesticides such as imidacloprid, polychlorinated biphenyls, environmental pollutants such as bisphenol A, toxic substances such as mycotoxin, osteocalcin (effective for diagnosing osteoporosis), corticoid, estradiol, aldosterone, lysozyme (chicken).
  • Biological materials such as egg white lysozyme) and drugs such as digoxin.
  • the sample may be any sample as long as it may contain the antigen to be detected, such as samples collected from humans (blood, saliva, urine, etc.), contaminated water or Examples thereof include soil, food and raw materials for food.
  • the method of contacting the sample with the biosensor and the method of detecting the formation of the multimer can be performed in the same manner as in the antibody detection biosensor described above.
  • CACCATCATCATCATCAT a DNA encoding His 6 (CACCATCATCATCATCAT) (SEQ ID NO: 4) was constructed by using two overlapping primers (His_NdeI_Back: AAGGAGACATACATATGCACCATCATCATCATCAT (SEQ ID NO: 5) and His_Hind_Forward: ACCGCCACCAAGCTTATGATGATGATGATGGTGCA (SEQ ID NO: 6)) by thermal cycling. ..
  • the His 6 -TM fusion sequence was constructed by overlap extension PCR using His_NdeI_Back and TM_Hind_Forward as primers and the His 6 and TM DNA obtained in the previous step as template.
  • the His 6 and His 6 -TM genes thus constructed were inserted into the NdeI / HindIII digested linear pET32 vector encoding the GUS_IV5_KY gene using the In-Fusion HD cloning kit (Clontech, Takara-Bio). As a result, two types of expression vectors His 6 -GUS_IV5_KY and His 6 -TM-GUS_IV5_KY were obtained (Fig. 1).
  • the GUS_IV5_KY gene is a gene encoding a mutant of Escherichia coli GUS containing 13 mutations of N27Y, F51Y, A64V, D185N, I349F, N369S, M516K, Y525F, G559S, K567R, F582Y, Q585H, and G601D.
  • Detection of enzyme activity (5.1) The liposome suspension was incubated at 37 ° C for 2 to 4 hours. (5.2) Centrifuge at 18,000 g for 30 minutes, discard the supernatant and add 150 ⁇ L of dilution buffer to resuspend the liposomes. (5.3) Add anti-His antibody (0.1 ⁇ M, anti-His 6 Mab28-75, Wako Pure Chemical Industries), 0.1 mg / mL fluorescein di- ⁇ -D-glucuronide, dimethyl ester (Marker Gene Technologies) to the liposome suspension.
  • anti-His antibody 0.1 ⁇ M, anti-His 6 Mab28-75, Wako Pure Chemical Industries
  • fluorescein di- ⁇ -D-glucuronide dimethyl ester
  • the present invention relates to biosensors, it can be used in the industrial field handling such biosensors.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention a pour objet de détecter un anticorps avec une sensibilité élevée; l'invention concerne un biocapteur permettant de détecter une liaison d'anticorps à un peptide, ledit biocapteur contenant 1) une protéine fusionnée contenant un mutant enzymatique activé par formation de multimère, un domaine transmembranaire et le peptide susmentionné et 2) une vésicule composée d'une membrane lipidique, caractérisé en ce que : A) le mutant enzymatique est un mutant ayant une mutation introduite dans celui-ci au moyen duquel l'affinité de liaison entre les monomères est abaissée; B) le domaine transmembranaire pénètre à travers la membrane lipidique de la vésicule; C) le mutant enzymatique activé par formation de multimère, est exposé à l'intérieur de la vésicule; et D) le peptide est exposé à l'extérieur de la vésicule.
PCT/JP2019/042761 2018-11-02 2019-10-31 Biocapteur WO2020090974A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018207624A JP7169582B2 (ja) 2018-11-02 2018-11-02 バイオセンサー
JP2018-207624 2018-11-02

Publications (1)

Publication Number Publication Date
WO2020090974A1 true WO2020090974A1 (fr) 2020-05-07

Family

ID=70462574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/042761 WO2020090974A1 (fr) 2018-11-02 2019-10-31 Biocapteur

Country Status (2)

Country Link
JP (1) JP7169582B2 (fr)
WO (1) WO2020090974A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1078436A (ja) * 1996-07-31 1998-03-24 Boehringer Mannheim Corp 抗原濃度測定方法
JP2004113062A (ja) * 2002-09-25 2004-04-15 Teruyuki Nagamune キメラ受容体を有する動物細胞とその利用
WO2017130610A1 (fr) * 2016-01-25 2017-08-03 国立大学法人東京工業大学 Protéine de fusion et procédé de détection d'antigène utilisant ladite protéine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147816A2 (fr) 2007-05-22 2008-12-04 Cornell Research Foundation, Inc. Compositions et procédés d'affichage de protéines sur la surface de bactéries et leurs vésicules dérivées et utilisations de celles-ci
JP7029123B2 (ja) 2016-08-24 2022-03-03 国立研究開発法人産業技術総合研究所 Ｓｉ－ｔａｇ融合異種酵素とメソポーラスシリカとの複合体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1078436A (ja) * 1996-07-31 1998-03-24 Boehringer Mannheim Corp 抗原濃度測定方法
JP2004113062A (ja) * 2002-09-25 2004-04-15 Teruyuki Nagamune キメラ受容体を有する動物細胞とその利用
WO2017130610A1 (fr) * 2016-01-25 2017-08-03 国立大学法人東京工業大学 Protéine de fusion et procédé de détection d'antigène utilisant ladite protéine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
UEDA, H. ET AL.: "An optimized homogeneous noncompetitive immunoassay based on the antigen-driven enzymatic complementation", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 279, 2003, pages 209 - 218, XP004455321, DOI: 10.1016/S0022-1759(03)00256-4 *
UEDA, HIROSHI ET. AL.: "Development of various highly sensitive homogeneous immunoassays by creating artificial allosteric enzymes", LECTURE ABSTRACTS OF THE 68TH ANNUAL MEETING OF THE SOCIETY OF BIOTECHNOLOGY, JAPAN, vol. 68, 25 August 2016 (2016-08-25), pages 160 *
YOKOZEKI, T. ET AL.: "A Homogeneous Noncompetitive Immunoassay for the Detection of Small Haptens", ANALYTICAL CHEMISTRY, vol. 74, no. 11, 1 June 2002 (2002-06-01), pages 2500 - 2504, XP001132315, DOI: 10.1021/ac015743x *

Also Published As

Publication number Publication date
JP7169582B2 (ja) 2022-11-11
JP2020068746A (ja) 2020-05-07

Similar Documents

Publication Publication Date Title
US20200339976A1 (en) Protease-resistant systems for polypeptide display and methods of making and using thereof
JP2020097597A (ja) 構造的相補性による生物発光の活性化
JP5323356B2 (ja) 高感度ｆｒｅｔセンサーの開発およびその使用方法
US7741128B2 (en) Cooperative reporter systems, components, and methods for analyte detection
US6235535B1 (en) Fluorescent energy transfer ligand interaction assay on a lipid film
WO2020090974A1 (fr) Biocapteur
JP2021515216A (ja) 溶液中の生物分子またはリガンドを検出し、定量化する生物発光バイオセンサー
KR20220121816A (ko) 다분할 루시퍼라제 펩타이드 및 폴리펩타이드
WO2009079212A2 (fr) Biocapteurs fluorogéniques de peptides liés
EP2141230B1 (fr) Protéine fusionnée étiquetée fluorescente pour dosage de l'adénosine triphosphate
JP6873483B2 (ja) 融合タンパク質及びそれを用いた抗原の検出方法
JP2007511226A (ja) 複数の成分検出のための共振エネルギ転移アッセイ・システム
US11499965B2 (en) Kit for detecting antigen or measuring its amount
JP2007040834A (ja) 免疫測定用試薬
US20180095076A1 (en) Linked Peptide Fluorogenic Biosensors
US8586315B2 (en) Fluorescent protein particles
CN101278194A (zh) 用于分析物检测的协同指示系统、组分以及方法
WO2020162203A1 (fr) Mutant enzymatique pour méthode d'immunoessai homogène
US20240140995A1 (en) Thermostable affinity polypeptides
US20100317032A1 (en) Method for detecting antigen and antigen detection device
EP2688912B1 (fr) Biodétecteurs de protéines recombinantes et procédé pour détecter la présence d'une molécule d'analyte
WO2023131871A1 (fr) Commutateurs à base de protéine allostérique de porte et
JP2004201526A (ja) 被検物質の体内残留性を検出する方法、核酸、蛋白質、細胞およびプローブ固定化チップ
JP5576585B2 (ja) リン酸化タンパク質免疫測定用試薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19878891

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19878891

Country of ref document: EP

Kind code of ref document: A1